Post hoc data show cariprazine improved both manic and depressive symptoms through 52 weeks in youth aged 10 to 17 years with bipolar I disorder.
News|Articles|October 1, 2026
Clinical trial news in pediatrics: September 2026
Author(s)Morgan Ebert, Executive Editor
Fact checked by: Benjamin P. Saylor
A recap of the top clinical trial and pipeline data readouts affecting pediatric care during September 2026.
Advertisement
Advertisement
September 2026's pediatric clinical trial readouts clustered heavily around growth and metabolic disorders. Three skeletal dysplasia programs — two in achondroplasia and one in hypochondroplasia — reported growth-velocity gains, while two GLP-1-class agents posted substantial BMI reductions in adolescents and in children as young as 6. Rare pediatric epilepsy, kidney disease, and eosinophilic esophagitis trials each delivered positive secondary or post hoc results, and a post-exposure COVID-19 antiviral's supporting phase 3 data rounded out the month.
Related to this article
Find out the 4 FDA decisions to watch in November 2026 for pediatric care.
Cenobamate sNDAs target PGTC seizures in patients ≥12 years and pediatric focal seizures; phase 3 PGTC data showed a 71.9% median reduction.
FDA approved Lupin's generic of Firdapse for LEMS in patients 6 years and older, but a patent settlement delays US marketing until at least 2035.
A recap of the top pediatric clinical trial results and pipeline data readouts during October 2026.
A recap of the top FDA approvals, regulatory decisions, and pipeline updates affecting pediatric care during October 2026.
In PROGRESS Cohort 2, zilurgisertib reduced total HO volume vs placebo at 24 weeks in children aged 6 to 11 with FOP, with no new HO lesions.
Registry data presented at ASN Kidney Week 2026 linked SCD-PED to higher 90-day survival vs historical controls in pediatric sepsis-associated AKI.
Advertisement
Advertisement